ClinicalTrials.gg
CompletedNCT02171000Updated Jun 23, 2014

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

A Phase 1 interventional study of BIBR 1048 MS in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-23.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

To investigate safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of multiple doses (150 mg b.i.d., 7 days)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12-lead , clinical laboratory tests

    • 1.1 No finding of clinical relevance
    • 1.2 No evidence of a concomitant disease
  2. Age ≥20 and Age ≤35 years
  3. (BMI) ≥18 and BMI \<25 kg/m2 (Body Mass Index)
  4. Signed and dated written prior to admission to the trial in accordance with Japanese GCP (Ministry of Health, Labour and Welfare Ordinance No.28, March 27, 1997).

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Subject was not able to use an adequate form of from the time of the first dose on Day 1 up to end-of study examination
  3. Diseases of the central nervous system (such as epilepsy), psychiatric disorders or neurological disorders
  4. History of orthostatic hypotension, clinically significant current or past fainting spells or blackouts.
  5. Chronic or relevant acute infections
  6. History of

    • allergy/ (including drug allergy) which was deemed relevant to the safety assessment as judged by the investigator (excluding asymptomatic seasonal rhinitis/hay fever)
    • any bleeding disorder including prolonged or habitual bleeding
    • other hematologic diseases
    • cerebral bleeding (e.g. after a car accident)
    • concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
  7. Intake of drugs with a long half-life (> 24 hours) within at least 1 month or less than 10 half-lives, whichever was shorter, of the respective drug prior to administration or during the trial
  8. Use of aspirin (including over-the-counter medications), antiplatelet agents like ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs, coumadin like anticoagulants, chronic use of , heparin or fibrinolytic agents within 14 days prior to administration up to end-of-study examination
  9. Participation in another trial with an drug within 3 months prior to administration up to end-of-study examination
  10. Smoker (>10 cigarettes/day or inability to refrain from smoking during the trial)
  11. Alcohol abuse (more than 60 g/day; confirmed by interview)
  12. Drug abuse (confirmed by interview)
  13. Blood donation (more than 100 mL from 3 months prior to screening and any blood donation from screening up to end-of-study examination)
  14. Excessive physical activities (within 7 days prior to the first drug administration up to end-of-study examination)
  15. Any laboratory value outside the reference range that was of clinical relevance
  16. Known hypersensitivity to the investigational drug or its
  17. Subject who was judged ineligible by the investigator or the sub-investigator
  18. History of any familial bleeding disorder
  19. \< 15 x 104 /μL
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    BIBR 1048

    BIBR 1048 MS

    Drug: BIBR 1048 MS

Interventions

  • 150 mg capsules, b.i.d, 7 days

    Also known as: dabigatran etexilate

06

What researchers measure

Primary outcomes

  1. Change from baseline in physical examination

    Time frame: within 14 days prior to drug administration until up to 18 days post drug administration

  2. Change from baseline in vital signs

    Time frame: within 14 days prior to drug administration until up to 18 days post drug administration

  3. Change from baseline in 12-lead electrocardiogram (ECG)

    Time frame: within 14 days prior to drug administration until up to 18 days post drug administration

  4. Change from baseline in clinical laboratory tests

    Time frame: within 14 days prior to drug administration until up to 18 days post drug administration

  5. Number of participants with adverse events

    Time frame: within 14 days prior to drug administration until up to 18 days post drug administration

Secondary outcomes

  1. Changes in activated partial thromboplastin time (aPTT)

    Time frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration

  2. Changes in ecarin clotting time (ECT)

    Time frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration

  3. Changes in thrombin time (TT)

    Time frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration

  4. Changes in prothrombin time expressed as international normalised ratio (INR)

    Time frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration

  5. Maximum measured concentration of the analyte in plasma (Cmax)

    Time frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration

  6. Time from dosing to maximum measured concentration of the analyte in plasma (tmax)

    Time frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration

  7. Area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on Day 1 (AUCτ,1)

    Time frame: Day 1 before, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after drug administration in the morning

  8. Amount of analyte that is eliminated in urine from the time point t1 to time point t2 ( Aet1-t2 )

    Time frame: Day 1: 0-4, 4-8, 8-12 and 12-24 hours after the first drug administration, on Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration

  9. Renal clearance of the analyte from the time point t1 until the time point t2 (CLR,t1-t2 )

    Time frame: Day 1: 0-4, 4-8, 8-12 and 12-24 hours after the first drug administration, on Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration

  10. Fraction of analyte eliminated in urine from time point t1 to time point t2 (fet1-t2)

    Time frame: Day 1: 0-4, 4-8, 8-12 and 12-24 hours after the first drug administration, on Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration

  11. Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  12. Time from last dosing to maximum concentration of the analyte in plasma at steady state (tmax,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  13. Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  14. Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  15. Terminal rate constant in plasma at steady state (λz,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  16. Terminal half-life of the analyte in plasma at steady state (t1/2,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  17. Mean residence time of the analyte in the body at steady state after po administration (MRTpo,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  18. Apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration (CL/F,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  19. Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

  20. Amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2 (Aet1-t2,ss)

    Time frame: Day 7 : 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration

  21. Fraction of analyte eliminated in urine at steady state from time point t1 to time point t2 (fet1-t2,ss)

    Time frame: Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration

  22. Renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state (CLR,t1-t2,ss)

    Time frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005 and a primary completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 23, 2014
Start
Apr 2005
Primary completionActual
May 2005
Last update
Jun 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171000
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Apr 2005
Primary completion
May 2005
Last update
Jun 23, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion